Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group reported 2025 revenue of HK$12.28 billion, up 5.5% year-on-year, or 14.8% excluding centralized procurement price cuts, with innovative and high-barrier products rising to about 50% of sales from 40% a year earlier. Adjusted net operating profit attributable to owners fell to HK$1.49 billion from HK$1.76 billion as price reductions trimmed gross profit by over HK$600 million and marketing spend rose by more than HK$500 million to support core innovative products and build a high-end, academic-focused sales network.
Management said the short-term impact of centralized procurement has been fully absorbed, with both full-year revenue and gross profit increasing, while intensified promotion has reinforced the market position and commercialization of core barrier products, underpinning medium- to long-term growth prospects. The group maintained its shareholder return focus with a proposed final dividend of HK$0.169 per share, driven alongside strong momentum in its nuclear medicine anti-tumor diagnosis and treatment segment, where revenue surged 61% to HK$948.87 million, and continued heavy R&D and project investment totaling about HK$1.46 billion.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated healthcare company listed in Hong Kong, focusing on pharmaceutical products with an increasing emphasis on innovative and high-barrier medicines. The group is actively upgrading its product mix toward original research, exclusive, and first-to-market generics to strengthen its long-term competitive position.
Average Trading Volume: 5,164,934
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.64B
See more data about 0512 stock on TipRanks’ Stock Analysis page.